{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"16.180","floor":"14.880"},"ipodate":{"start":"2020-04-14 00:00:00","end":"2020-04-17 00:00:00"},"minimumcapital":"16343.05","subscribed":"639.20","marketcap":"123.47億","H_marketcap":"--","pe":"--","codesrate":"12.00","link":"https://staticpdf.iqdii.com/stockdata/notice/09926/2020/2020041400146_c.pdf","ipopricing":"16.180","resultdate":"2020-04-23 00:00:00","enddate":"2020-04-17 00:00:00","listeddate":"2020-04-24 00:00:00","issuenumber":"15949.50萬","issuenumberhK":"7974.80萬","issuenumberother":"7974.70萬","grayprice":"23.80","sponsors":"摩根士丹利亞洲有限公司,摩根大通證券(遠東)有限公司","raisemoney":"243690.00萬","use":"1、約75.0%，或1,827.7百萬港元，將主要用于以下產品研發及商業化；\n2、約15.0%，或365.5百萬港元，將用于在中國廣州及中山發展生產及研發設施，其中大部分將用于購買新機器、儀器及設備以及擴展生產設施；\n3、約10.0%，或243.7百萬港元，將用于我們的一般公司及營運資金用途。","shares":1000,"leadagent":"摩根士丹利亞洲有限公司,摩根大通證券(亞太)有限公司,交銀國際證券有限公司,中國國際金融香港證券有限公司,中銀國際亞洲有限公司,招銀國際金融有限公司,招商證券(香港)有限公司","bookrunners":"摩根士丹利亞洲有限公司,摩根大通證券(亞太)有限公司,交銀國際證券有限公司,中國國際金融香港證券有限公司,中銀國際亞洲有限公司,招銀國際金融有限公司,招商證券(香港)有限公司","coordinator":"摩根士丹利亞洲有限公司,摩根大通證券(亞太)有限公司,交銀國際證券有限公司,中國國際金融香港證券有限公司","firstDayOpen":"23.50","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E09926","name":"康方生物－Ｂ","fullname":"康方生物科技(開曼)有限公司"},"institutioninfo":{"principaloffice":"中國廣東省中山市火炬開發區神農路6號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"夏瑜","secretary":"席曉捷,孫佩真","telephone":"(86760) 8987 3998","substantialshareholders":"夏氏特殊目的實體及信托(10.58%),李氏特殊目的實體及信托(7.16%),王氏特殊目的實體及信托(6.19%),Aquae Hyperion Limited(5.93%)","principalactivities":"公司是一家臨床階段生物制藥公司，致力于首創及同類最佳療法的自主發現、開發及商業化。","website":"http://www.akesobio.com"},"managerinfo":[{"managername":"夏瑜","post":"主席、首席執行官、總裁兼執行董事","rankno":1},{"managername":"李百勇","post":"首席科學官、高級副總裁兼執行董事","rankno":2},{"managername":"王忠民","post":"高級副總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"Fidelity International","shareholding":"31,373,000.0","percentage":19.67,"ReleaseDate":"2020-10-24 00:00:00","relatedparty":"富達基金(香港)有限公司","subsidiary":["Fidelity International"],"InverstorType":"基金"},{"institutionname":"Lake Bleu Prime Healthcare Master Fund Limited","shareholding":"21,720,000.0","percentage":13.62,"ReleaseDate":"2020-10-24 00:00:00","relatedparty":"清池資本(香港)有限公司","subsidiary":["Lake Bleu Prime Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"OrbiMed Funds","shareholding":"7,240,000.0","percentage":4.54,"ReleaseDate":"2020-10-24 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"Hudson Bay Master Fund LTD","shareholding":"4,826,000.0","percentage":3.03,"ReleaseDate":"2020-10-24 00:00:00","relatedparty":"Hudson Bay Capital Management LP","subsidiary":["HBC Asia Healthcare Opportunities V LLC","Hudson Bay Master Fund LTD","HBC Asia Healthcare Opportunities VII LLC"],"InverstorType":"基金"}],"TotalShareholdingPercentage":49.33},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}